Jasty v. Wright Medical Technology, Inc.

528 F.3d 28, 2008 U.S. App. LEXIS 11980, 2008 WL 2284835
CourtCourt of Appeals for the First Circuit
DecidedJune 5, 2008
Docket07-1743, 07-1744
StatusPublished
Cited by63 cases

This text of 528 F.3d 28 (Jasty v. Wright Medical Technology, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jasty v. Wright Medical Technology, Inc., 528 F.3d 28, 2008 U.S. App. LEXIS 11980, 2008 WL 2284835 (1st Cir. 2008).

Opinion

HOWARD, Circuit Judge.

Appellants Wright Medical Technology, Inc. and Wright Medical Group, Inc. (collectively, “Wright”) challenge the district court’s summary judgment ruling that Wright breached its contract with Dr. Mu-rali Jasty, as well as the district court’s refusal to consider newly submitted facts on review of the report and recommendation of a magistrate judge. Jasty’s cross-appeal challenges the district court’s summary judgment ruling that Wright did not violate state consumer protection statutes. Jasty also challenges the district court’s decision not to compel a Wright expert to testify, as well as the court’s choice of law ruling with respect to the calculation of prejudgment interest on a damages award. We affirm the district court across the board.

I. Facts.

A. Background. 1

Tennessee-based Wright Medical Technology, Inc. designs, manufactures and markets orthopedic implant devices. Dr. Murali Jasty, an orthopedic surgeon associated with Massachusetts General Hospital, was one of a group of surgeons nationwide whom Wright engaged to act as consultants and to help Wright develop and commercialize a new artificial knee system, the “ADVANCE® Knee.” In March 1995 Wright entered into a written contract with Jasty. Under the contract, Wright agreed to compensate Jasty for providing a variety of services in support of the development of the Advance Knee.

Jasty’s responsibilities, as set forth in the first paragraph of the contract, were to “act as a designer, product spokesperson and consultant.” He agreed to provide Wright with “sendees and expertise” including but not limited to:

(a)Current clinical design or other experience with total knee systems ...
(b) Time away from [his] practice necessary to participate in clinical consultant meetings and/or technical meetings ...
(c) Time necessary to review and coauthor papers and publications ... (d) Time necessary to develop product educational information ... (e) ... [R]e-viewfing] clinical data and mak[ing] oral presentations to peer groups, regulatory agencies and the general public as required ... [and] (f) ... [P]rovid[ing], at Wright’s request, regular written activity reports.

Compensation was to take three different forms: 1) a flat payment, for the peri *31 od November 1,1994 through November 1, 1999, of $145,000 per year; 2) royalty payments for ten years based on sales of the Advance Knee; and 3) specified payments on the date of and subsequent anniversaries of Wright’s initial public offering (“IPO”), should Wright become a publicly traded company. The $145,000 annual payment for the period November 1994 to November 1999 was expressly designated as payment “in return for the above services,” that is, those set out in the first paragraph. The contract further specified with respect to that annual payment, “Payment of this sum is to compensate you for spending time away from your practice to provide such services and consultations to [Wright] during that period as well as to compensate you for your design input and the rights to commercialize ... your rights to inventions currently under patent.” After November 1999, “all payments for services under this Agreement shall be pursuant to paragraph 2.b. (and paragraph 2.d. if applicable).” Paragraphs 2.b. and 2.d. provide for the royalty and IPO payments. The contract also provided for an offset: should royalties based on sales be payable prior to November 1, 1999, the annual payments would be reduced by the amount of the royalty payments.

Under the royalty provision, Jasty would be entitled to royalties “[w]hen a component of the Products results from these collaborative efforts for which you have contributed significant design input.” Royalties were to be paid quarterly for ten years, based on a specified percentage of net sales. This provision contains no language about Jasty’s services or any other conditions, other than the requirement that Jasty must have contributed “significant design input.”

The IPO compensation provision establishes cash payments if Wright were to become a public company. The first payment of $100,000 would be made at the time of the IPO. Later payments of $50,000 each were to be made on the first two anniversaries of the IPO date, with another payment of $100,000 to be made on the third anniversary. The IPO payments were to be triggered only if Jasty was “continuing to perform consulting services to [Wright] under this agreement at the time of payment, unless such nonperformance is due to death or disability”.

Under the contract’s termination provision, termination for cause may be by either party on thirty days written notice and after an opportunity to cure. The contract could also be terminated for cause without written notice and opportunity to cure for failure to comply with paragraph 5, the contract’s exclusivity provision. That provision prohibited Jasty from working on competitor products. Additionally, the contract contained an as-of-right termination provision for Jasty: on November 1, 1999, Jasty would become free to terminate the contract.

It is undisputed that Jasty contributed to the development of the Advance Knee and was eligible for royalties. 2 He began receiving royalty payments under the contract in the second quarter of 1995. Wright also made all of the required $145,000 annual payments to Jasty between November 1994 and November 1999.

*32 The first sign of trouble in the consulting relationship appeared in October 1998. Wright’s then-President and CEO Tom Patton traveled to Boston to meet with Jasty to discuss Jasty’s work. Patton testified in his deposition that he informed Jasty of Wright’s dissatisfaction with his performance and that his contract would be terminated if he did not conform his performance to expected standards.

Contemporaneously, Patton sent Jasty a letter purporting to summarize the meeting. In the letter, Patton stated, “I am glad we had the opportunity to meet last week and discuss your ongoing role with our business.” The letter also mentioned Patton’s intention to “reduce our discussions to writing.”

The letter continued: “[0]n-going promotional, marketing and scientific services from you are critical to the success of the Advance Knee, have always been contemplated by our agreement, and provide the basis for continued payments under our contract.” The letter stated that Patton and Jasty “agreed that it was important for [Jasty] to do” the following: “use the Advance Knee in the majority of your knee cases,” “host surgeons for surgical demonstrations,” “develop published studies from your lab” and “make yourself more readily available to speak.” In the letter, Patton also expressed the view that Jasty’s work in developing and promoting a competing product was “unacceptable.”

The letter contained no threat of termination. It did not state that Wright considered Jasty in breach of the contract, nor did it mention a thirty-day time frame or an opportunity for Jasty to cure. The letter did advise Jasty that Wright personnel would contact him regarding specific projects.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
528 F.3d 28, 2008 U.S. App. LEXIS 11980, 2008 WL 2284835, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jasty-v-wright-medical-technology-inc-ca1-2008.